Moneycontrol PRO
HomeNewsBusinessEarningsWorst over on US pricing pressure: Lupin tells Rakesh Jhunjhunwala in an interaction

Worst over on US pricing pressure: Lupin tells Rakesh Jhunjhunwala in an interaction

India’s second-largest drug maker on Tuesday posted a massive net loss of Rs 783.5 crore in the fourth quarter ended March due to a one-time impairment provision on certain made on certain intangible assets related to Gavis acquisition in US.

May 16, 2018 / 15:25 IST
rakesh_jhunjhunwala1
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    The management of Lupin believes the worst may be over on drug pricing pressures in the US, the company told investors in an interaction after reporting its quarterly earnings.

    India’s second-largest drugmaker on Tuesday posted a massive net loss of Rs 783.5 crore in the fourth quarter ended March due to a one-time impairment provision on made on certain intangible assets related to the Gavis acquisition in the US.

    Ace investor Rakesh Jhunhjhunwala, who holds 1.92 percent stake in Lupin, was among those who quizzed the management on pricing pressure.

    "I won't say that price erosion is gone but I'll say that days of double-digit price erosion, we are hoping, are behind us,” Vinta Gupta, CEO of Lupin, said during the talk.

    Increasing competition and a consolidating customer base have been hurting profits at generic drug makers supplying to the US, the world’s largest healthcare market.

    So much that many large companies, such as Teva and Novartis, are even considering putting their generics business on the block.

    "Companies have started getting out of portfolios that don't make sense,” she told Jhunjhunwala during the call.

    Additionally, she said that customers were also accommodative of the fact that the industry has reached a pain point and added that balance needs to shift.

    “We are addressing pockets of our portfolio where we have pressures and are working with our channel partners, our customers to see how we can work together to ensure sustainable supply,” she added.

    The company reported a net profit of Rs 383.6 crore in the year-ago quarter. The sales fell 2.8 percent to Rs 4,179 crore.

    A Reuters poll of analysts estimated net profit to Rs 323.8 crore in the fourth quarter, while revenues at Rs 3,952 crore.

    The company took an impairment of 1464.3 crore on Gavis.

    Excluding one-time impairment provision, the net profit of Lupin stood at Rs 358.6 crore, higher than analyst estimates.

    (With inputs from Reuters)

    Moneycontrol News
    first published: May 16, 2018 02:22 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347